Erin McEvoy

Our sister publication, Nutritional Outlook, covered the science, safety, regulatory challenges, and therapeutic potential of nonpsychoactive cannabinoids including CBN, CBG, and CBDA.

Researchers assess how often consumers talk with general practitioners about cannabis and the public health implications.

Governor DeWine issues a 90-day emergency ban on intoxicating hemp products in Ohio to protect minors and public health.

Trump highlights hemp-derived CBD for senior healthcare, sparking discussion on cannabis reform, Medicare coverage, and the endocannabinoid system.

A new Smart Approaches to Marijuana poll shows most Americans oppose cannabis rescheduling if it increases youth advertising or benefits foreign cartels.

Our top five cannabis and hemp news this week: cannabis sales milestones in Minnesota and Virginia, new CBD research, and Colorado’s latest regulatory updates.

Research highlights benefits of hemp-derived CBD reported by patients with anxiety: reduced anxiety, better sleep, and improved mood.

A new literature review highlights CBD’s potential in skin health, from acne to psoriasis, while exploring delivery challenges and future applications.

New research shows frequent cannabis users may drive as well as non-users after abstinence.

The Virginia Cannabis Control Authority reported data on medical cannabis sales and most popular products for July to August 2025.

Our top five cannabis and hemp news this week: OCM fines NY lab, Congress halts rescheduling funding, Texas issues hemp order, NJ supports businesses with $15M in funding, and our latest podcast episode.

A UK Medical Cannabis Registry study found cannabis-based medicines improved sleep, anxiety, and quality of life in insomnia patients.

According to the Division of Cannabis Control, medical marijuana sales exceeded $2.2 billion and recreational cannabis generated over $785 million since legalization.

Clinical and in vitro analysis shows THC may impair female fertility, distrupting oocyte development and affecting IVF outcomes.

The FY26 CJS Appropriations Act includes Section 607, barring cannabis rescheduling. Advocates warn the Act threatens medical cannabis protections.

Our top five cannabis and hemp news this week: Nebraska’s medical cannabis battle, rescheduling debate, Thailand policy shifts, new medical cannabis research, and pricing trends.

This month’s Healer webinar, led by Dustin Sulak, DO, explores new medical cannabis research including potential benefits for cancer, wound healing, ALS, Alzheimer’s, and terpenes like alpha-pinene.

In this interview, Steve Allin, director of the International Hemp Building Association shares insights on the versatility and benefits of hemp as a crop and as a material used in construction.

An examination of survey data finds state cannabis laws strongly shape delta-8-THC use, with highest rates in prohibition states.

Citing risks to children, health, and public safety, nine Congress members sent a letter to Attorney General Pam Bondi and President Donald Trump, opposing the rescheduling of cannabis.

Here, we bring you our top five recent articles covering federal hemp ban, an interview with Reginald Gaudino, PhD, the reintroduced MORE Act, Delaware cannabis sales and rezoning, and restricting intoxicating hemp-derived cannabinoids.

Recent research highlights the potential of cannabinoids as alternative treatments for atopic dermatitis, showcasing their anti-inflammatory and antibacterial properties.

The organization voiced its support of Texas and other states restricting synthetic hemp cannabinoids, urging science-based regulation to protect consumers, businesses, and public safety.

As more studies are being conducted on multiple parts of the cannabis plant, this study tested the root samples against four cancer cell lines, finding evidence of antiproliferation effects.

Hemp has the potential to be a sustainable resource for textiles and building materials, but it still has to overcome the stigma and regulatory hurdles that challenge its widespread adoption.

Here, we bring you our top five recent articles covering a $3.6 million grant for Minnesota’s cannabis industry, kidney disease and cannabis use, banking reform, flavoalkaloids in leaves, and CBD and liver enzyme levels.

Two organizations with opposing views recently prepared letters to the Trump Administration on the anticipated action regarding cannabis reclassification.

In collaboration with the California Department of Cannabis Control (DCC), the new feature is anticipated to increase direct access to recall information.

Using an optimized analytical method for this research, the phenolics of cannabis were tested resulting in new findings.

The FDA-funded study found that CBD was linked to elevated liver enzymes in some healthy adults, underscoring need for further safety research.